Биология ва тиббиёт муаммолари 2024 №1 (151)

Subject of the article

ПРОСТАТА БЕЗИ САРАТОНИНИНГ ЮРАК ҚОН-ТОМИР ТИЗИМИ КАСАЛЛИКЛАРИ ВА 2-ТИП ҚАНДЛИ ДИАБЕТ БИЛАН ЎЗАРО БОҒЛИҚЛИГИ (436-443)

Authors

Тилляшайхов Мирзагалеб Нигматович, Алимов Жалолиддин Усмонхон ўғли

Institution

1 - Республика ихтисослаштирилган онкология ва радиология илмий – амалий тиббиёт маркази, Ўзбекистон Республикаси, Тошкент ш.; 2 – Самарқанд давлат тиббиёт университети, Ўзбекистон Республикаси, Самарқанд ш.

Abstract

Саратон бутун дунё бўйлаб касалланиш ва ўлимнинг асосий сабабларидан бири ҳисобланади. Саратон касаллигини ўрганиш бўйича халқаро агентликнинг GLOBOCAN 2020 ҳисоботига кўра, дунёнинг 20 минтақаси, шу жумладан Россиянинг рўйхатга олиш натижалари билан тақдим этилган простата саратони (ПБС) энг кэнг тарқалганлардан бири эканлиги қайд этилди. У эркаклар орасида энг кўп учрайдиган раклар орасида 2-ўринни ва барча раклар ичида 4-ўринни эгаллайди. Простата саратонидан ўлим даражаси кўплаб мамлакатларда, шу жумладан Шимолий Америка, Шимолий ва Ғарбий Эвропа, Осиёнинг ривожланган мамлакатларида (GLOBOCAN 2020 ҳисоботига кўра) камайиб бораётган бўлса-да, бутун дунё бўйлаб ўлим сони бўйича ушбу саратон ўпка раки, кўкрак безлари раки ва колоректал ракдан сўнг 4-ўринни эгаллаб келмоқда. Иккала жинсдаги барча аҳоли орасида ПБС ўлим сони бўйича 8-ўринни эгаллайди (358 989 киши, 3,8%). Россияда трахея, бронхлар ва ўпка ўсмаларидан кейин 2-ўринни эгаллаган простата бези саратонидан ўлим кўрсаткичларининг ўсиши давом этмоқда.

Key words

простата бези саратони, юрак қон-томир тизими касалликлари, 2-тип қандли диабет.

Literature

1. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации (Вып. 9) // Сахарный диабет. - 2019. - Т. 22. - №S1. - С.1-144. https://doi.org/10.14341/ DM221S1 2. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 3. Пешков М.Н., Пешкова Г.П., Решетов И.В. Взаимосвязь рака предстательной железы и са-харного диабета второго типа. Сахарный диабет. 2021;24(6):583-591. https:// doi.org/10.14341/DM12672 4. Помешкина С.А., Барбараш О.Л., Помешкин Е.В., БрагинМальцев А.И. Механизмы взаимосвязи атеросклероза и рака предстательной железы: обзор литературы. CardioСоматика. 2023. Т. 14, № 1. С. 49-58. DOI: https:// doi.org/10.17816/CS195493 5. Abdollah F., Sammon J.D., Reznor G., et al. Medical androgen deprivation therapy and increased non-cancer mortality in nonmetastatic prostate cancer patients aged ≥66 years // Eur J Surg Oncol. 2015. Vol. 41, N 11. P. 1529– 1539. doi: 10.1016/ j.ejso.2015.06.011 6. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease // Ther Adv Chronic Dis. 2014. Vol. 5, N 4. P. 178–187. doi: 10.1177/2040622314529325 7. Aggarwal B.B., Shishodia S., Sandur S.K., et al. Inflammation and cancer: how hot is the link? // Biochem Pharmacol. 2006. Vol. 72, N 11. P. 1605–1621. doi: 10.1016/j.bcp.2006.06.029 8. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101:1272-1279. https:// doi.org/10.1093/jnci/djp260 9. Allott E.H., Masko E.M., Freedland S.J. Obesity and prostate cancer: Weighing the evidence // Eur Urol. 2013. Vol. 63, N 5. P. 800–809. doi: 10.1016/j.eururo.2012.11.013 10. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diabetes Res. 2012;2012:1-12. https:// doi.org/10.1155/2012/789174 11. Asia Pacific Cohort Studies Collaboration; Huxley R., Ansary-Mohaddam A., et al. The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region // Asian Pac J Cancer Prev. 2007. Vol. 8, N 2. P. 199–205. 12. Attner B, Landin-OlssonM, LithmanT, et al. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control. 2012;23(5):769-777 https://doi.org/10.1007/ s10552-012-9946-5 13. Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a metaanalysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151-158. https:// doi.org/10.1038/pcan.2012.40 14. Batty G.D., Kivimaki M., Clarke R., et al. Modifiable risk factors for prostate cancer mortality in London. forty years of follow-up in the Whitehall study // Cancer Causes Control. 2011. Vol. 22, N 2. P. 311–318. doi: 10.1007/ s10552-010-9691-6 15. Bhatia N., Santos M., Jones L.W., et al. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer // Circulation. 2016. Vol. 133, N 5. P. 537– 541. doi: 10.1161 / CIRCULATIONAHA. 115.012519 16. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071-1078. https:// doi.org/10.1007/ s00125-004-1415-6 17. Cattabiani C, Basaria S, Ceda GP. Luci, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35:104-120. https:// doi.org/10.3275/8061 18. Chen Y, Chen Q, Wang Z, Zhou J. Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and MetaAnalysis of Observational Studies. PLoS One. 2013;8(11):e81594. https:// doi.org/10.1371/ journal.pone.0081594 19. Cheng C., Geng F., Cheng X., Guo D. Lipid metabolism reprogramming and its potential targets in cancer // Cancer Commun (Lond). 2018. Vol. 38, N 1. P. 27. doi: 10.1186/s40880-018-0301-4 20. Dankner R, Boffetta P, Balicer RD, et al. Time-dependent Risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098-1106. https://doi.org/10.1093/aje/ kwv290 21. Darbinian JA, Ferrara AM, Van Den Eeden SK, et al. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:628-635. https:// doi.org/10.1158/1055-9965.EPI-07-2610 22. Davis M.K., Rajala J.L., Tyldesley S., et al. The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada // J Oncol.2015. N 2015. P. 820403. doi: 10.1155/2015/820403 23. de Nigris F., Sica V., Herrmann J., et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in сancer and cardiovascular disease // Cell Cycle. 2003. Vol. 2, N 4. P. 325–328. 24. Di Francesco S., Robuffo I., Caruso M., et al. Metabolic Alterations, Aggressive Hormone-Naпve Prostate Cancer and Cardiovascular Disease: A Complex Relationship // Medicina (Kaunas). 2019. Vol. 55, N 3. P. 62. doi: 10.3390/ medicina55030062 25. Di Sebastiano KM, Bell KE, Mitchell AS, et al. Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. Clin Nutr. 2018;37(1):195-203. https:// doi.org/10.1016/ j.clnu.2016.11.024 26. Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, et al. Elevated c-peptides, abdominal obesity and abnormal adipokine profile are associated with higher Gleason scores in prostate cancer. Prostate. 2017;77:211-221. https:// doi.org/10.1002/pros.23262 27. Dixon S., Stockwell B.R. The role of iron and reactive oxygen species in cell death // Nat Chem Biol. 2014. Vol. 10, N 1. P. 9–17. doi: 10.1038/ nchembio.1416 28. Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk; a nation wide casecontrol study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-1109 https:// doi.org/10.1158/1055-9965.EPI-12-1046 29. Farwell W.R., D’Avolio L.W., Scranton R.E., et al. Statins and prostate cancer diagnosis and grade in a veterans population // J Natl Cancer Inst. 2011. Vol. 103, N 11. P. 885–892. doi: 10.1093/jnci/djr108 30. Galbraith L., Leung H.Y., Ahmad I. Lipid pathway deregulation in advanced prostate cancer // Pharmacol Res. 2018. N 131. P. 177–184. doi: 10.1016/ j.phrs.2018.02.022 31. Hager M., Mikuz G., Bartsch G., et al. The association between local atherosclerosis and prostate cancer // BJU Int. 2007. Vol. 99, N 1. P. 46–48. doi: 10.1111/ j.1464-410X.2006.06549.x 32. Jian Gang P, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative metaanalysis. Endocr Res. 2015;40(1):54-61. https:// doi.org/10.3109/07435800.2014.934961 33. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056-2062. https:// doi.org/10.1158/1055-9965.EPI-06-0410 34. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. https://doi.org/10.1200/ JCO.2006.06.2497 35. Khan M.A., Hashim M.J., Mustafa H., et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study // Cureus. 2020. Vol. 12, N 7. P. e9349. doi: 10.7759/ cureus.9349 36. Kitahara C.M., Berrington de Gonzalez A., Freedman N.D., et al. Total cholesterol and cancer risk in a large prospective study in Korea // J Clin Oncol. 2011. Vol. 29, N 12. P. 1592–1598. doi: 10.1200/ JCO.2010.31.5200 37. Lai GY, Park Y, Hartge P, et al. The association between selfreported diabetes and cancer incidence in the NIHAARP diet and health study. J Clin Endocrinol Metab. 2013;98(3):E497-E502. https:// doi.org/10.1210/jc.2012-3335 38. Lawrence YR, Morag O, Benderly M, et al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16(2):181-186. https:// doi.org/10.1038/pcan.2012.54 39. Libby P. Mechanisms of acute coronary syn-dromes and their implications for therapy // N Engl J Med. 2013. Vol. 368, N 21. P. 2004–2013. doi: 10.1056/NEJMra1216063 40. Magliano DJ, Davis WA, Shaw JE, et al. Inci-dence and predictors of all-cause and sitespecific cancer in type 2 diabetes: the Fremantle diabetes study. Eur J Endocrinol. 2012;167(4):589-599. https:// doi.org/10.1530/EJE-12-0053 41. Matthes K.L., Pestoni G., Korol D., et al. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study // Urol Oncol. 2018. Vol. 36, N 6. P. 309.e15–309.e23. doi: 10.1016/j.urolonc.2018.02.016 42. Mondul A.M., Clipp S.L., Helzlsouer K.J., Platz E.A. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort // Cancer Causes Control. 2010. Vol. 21, N 1. P. 61–68. doi: 10.1007/ s10552-009-9434-8 43. Moses K A, Utuama O A, Goodman M, et al. The association of diabetes and positive prostate biopsy in a US veteran population Prostate Cancer. Prostatic Dis. 2012;15(1):70-74 https:// doi.org/10.1038/pcan.2011.40 44. Ouimet M. Autophagy in obesity and atherosclerosis: Interrelationships between cholesterol homeostasis, lipoprotein metabolism and autophagy in macrophages and other systems // Biochim Biophys Acta. 2013. Vol. 1831, N 6. P. 1124–1133. doi: 10.1016/j.bbalip.2013.03.007 45. Pelton K., Freeman M.R., Solomon K.R. Cholesterol and Prostate Cancer // Curr Opin Pharmacol. 2012. Vol. 12, N 6. P. 751–759. doi: 10.1016/ j.coph.2012.07.006 46. Perks CM, Zielinska HA, Wang J, et al. Insulin receptor isoform variations in prostate cancer cells. Front Endocrinol. 2016;7:132. https:// doi.org/10.3389/ fendo.2016.00132 47. Platz E.A., Clinton S.K., Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era // Int J Cancer. 2008. Vol. 123, N 7. P. 1693–1698. doi: 10.1002/ijc.23715 48. Preston MA, Riis AH, Ehrenstein V, et al. Met-formin use and prostate cancer risk. Eur Urol. 2014; 66:1012-1020. https://doi.org/10.1016/ j.eururo.2014.04.027 49. Ross S., Stagliano N.E., Donovan M.J., et al. Atherosclerosis and cancer: common molecular pathway of disease development and progression // Ann N Y Acad Sci. 2001. N 947. P. 271–292. Discussion 292–293. 50. Roth G.A., Johnson C., Abajobir A., et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 // J Am Coll Cardiol. 2017. Vol. 70, N 1. P. 1–25. doi: 10.1016/ j.jacc.2017.04.052 51. Samueal VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016;1(26):12-22. https://doi.org/10.1172/ JCI77812 52. Sarrazy V., Sore S., Viaud M., et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation // Cell Rep. 2015. Vol. 13, N 1. P. 132–144. doi: 10.1016/ j.celrep.2015.08.068 53. Shafique K., McLoone P., Qureshi K., et al. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up // BMC Cancer. 2012. N 12. P. 25. doi: 10.1186/1471-2407-12-25 54. Shin D.W., Ahn E., Kim H., et al. Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study // Cancer Causes Control. 2010. Vol. 21, N 6. P. 919–929. doi: 10.1007/ s10552-010-9521-x 55. Simons K., Vaz W.L. Model systems, lipid rafts, and cell membranes // Annu Rev Biophys Biomol Struct. 2004. N 33. P. 269–295. doi: 10.1146/ annurev.biophys.32.110601.141803 56. Sosa V., Molinй T., Somoza R., et al. Oxidative stress and cancer: An Overview // Ageing Res Rev. 2013. Vol. 12, N 1. P. 376–390. doi: 10.1016/ j.arr.2012.10.004 57. Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71,N 3. P. 209–249. doi: 10.3322/ caac.21660 58. Tall A.R., Yvan-Charvet L. Cholesterol, inflammation and innate immunity // Nat Rev Immunol. 2015. Vol. 15, N 2. P. 104–116. doi: 10.1038/nri3793 59. Tapia-Vieyra J.V., DelgadoCoello B., Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications // Arch Med Res. 2017. Vol. 48, N 1. P. 12–26. doi: 10.1016/ j.arcmed.2017.03.005 60. Tekdoğan UY, Bağcioğlu M, Özcan S, et al. The effect of oral glucose tolerance test on insulin and some related indicators in elderly male patients with prostate cancer and benign prostate hyperplasia. Turkish J Geriatrics. 2015;18:10-14. 61. Thomas J.A. 2nd, Gerber L., Baсez L.L., et al. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study // Cancer Epidemiol Biomarkers Prev. 2012. Vol. 21, N 4. P. 576–581. doi: 10.1158/1055-9965.EPI-11-1017 62. Tosi M.R., Bottura G., Lucchi P., et al. Cholesteryl esters in human malignant neoplasms // Int J Mol Med. 2003. Vol. 11, N 1. P. 95–98. doi: 10.3892/ ijmm.11.1.95 63. Tsilidis KK, Allen NE, Appleby PN, et al Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition Int J Cancer. 2015;136(2):372-381. https://doi.org/10.1002/ ijc.28989 64. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. https://doi.org/10.1136/ bmj.g7607 65. Van Hemelrijck M., Garmo H., Holmberg L., et al. Prostate cancer risk in the Swedish AMORIS study. the interplay among triglycerides, total cholesterol, and glucose // Cancer. 2011. Vol. 117, N 10. P. 2086–2095. doi: 10.1002/ cncr.25758 66. Van Hemelrijck M., Walldius G., Jungner I., et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study // Cancer Causes Control. 2011. Vol. 22, N 7. P. 1011–1019. doi: 10.1007/s10552-011-9774-z 67. Vidal-Vanaclocha F. Inflammation in the molecular pathogenesis of cancer and atherosclerosis // Reumatol Clin. 2009. Vol. 5, Suppl. 1. P. 40–43. doi: 10.1016/ j.reuma.2008.12.008 68. Virmani R., Kolodgie F.E., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage // Arterioscler Thromb Vasc Biol. 2005. Vol. 25, N 10. P. 2054–2061. doi: 10.1161/01.ATV.0000178991.71605.18 69. Wallis C.J., Mahar A.L., Satkunasivam R., et al. Cardiovascular and Skeletalrelated Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation // Urology. 2016. N 97. P. 145–152. doi: 10.1016/j.urology.2016.08.002 70. Writing Group Members; Mozaffarian D., Benjamin E.J., et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association // Circulation. 2016. Vol. 133, N 4. P. e38– 360. doi: 10.1161/ CIR.0000000000000350 71. Yadav L., Puri N., Rastogi V., et al. Tumour angiogenesis and angiogenic inhibitors: a review // J Clin Diagn Res. 2015. Vol. 9, N 6. P. XE01–XE05. doi: 10.7860/ JCDR/2015/12016.6135 72. Yusuf S., Rangarajan S., Teo K., et al., Cardio-vascular risk and events in 17 low-, middle-, and high-income countries // N Engl J Med. 2014. Vol. 371, N 9. P. 818–827. doi: 10.1056/NEJMoa1311890 73. Zamboni PF, Simone M, Passaro A, et al. Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. Horm Metab Res. 2003;35:296-300. https:// doi.org/10.1055/s-2003-41305 74. Zaorsky N.G., Churilla T.M., Egleston B.L., et al. Causes of death among cancer patients // Ann Oncol. 2017. Vol. 28, N 2. P. 400–407. doi: 10.1093/ annonc/mdw604 75. Zhang X., Li G., Hu L., et al. Resistive index of prostatic capsular arteries as a predictor of prostate cancer in patients undergoing initial prostate biopsy // Med Oncol. 2014. Vol. 31, N 12. P. 297. doi: 10.1007/s12032-014-0297-9 76. Zhivotovsky B., Orrenius S. Cell cycle and cell death in disease: past, present and future // J Intern Med. 2010. Vol. 268, N 5. P. 395–409. doi: 10.1111/ j.1365-2796.2010.02282.x